Targeting the HIF-1/ASC pathway with dapagliflozin protects against sleep apnea-exacerbated myocardial damage in heart failure

30 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Heart failure therapies: current drug strategies Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by